Key result
Continuous intravenous unfractionated heparin reduced markers of fibrin formation and fibrinolysis more rapidly than once-daily subcutaneous nadroparin in patients with proximal DVT (p < 0.05).
Why the study?
Does unfractionated heparin reduce markers of hemostatic activation more rapidly than nadroparin in patients with proximal deep vein thrombosis?
Population
20 patients with proximal deep vein thrombosis confirmed by duplex ultrasound and phlebography
Comparison
Unfractionated heparin given as an intravenous… vs Nadroparin 185 AXa IU/kg once daily…
Design
RCT, randomly assigned
Follow-up
4 days
Authors
Loading...
Supports initial continuous IV UFH for rapid hemostatic control in proximal DVT; extends UFH-LMWH comparisons on fibrin markers.
RCT (n=20)
Randomly assigned
Does unfractionated heparin reduce markers of hemostatic activation more rapidly than nadroparin in patients with proximal deep vein thrombosis?
p-value: p=< 0.05
Continuous intravenous unfractionated heparin controls markers of the hemostatic system more rapidly than once-daily subcutaneous nadroparin in the initial treatment of proximal deep vein thrombosis.
Marchetti et al. (1999) conducted an RCT in Proximal deep vein thrombosis (n=20). Unfractionated heparin (UH) vs. Nadroparin (185 AXa IU/kg once daily subcutaneously) was evaluated on Time course of markers of hemostatic activation (F1+2, FPA, TAT, D-dimer) (p=< 0.05). Continuous intravenous unfractionated heparin reduced markers of fibrin formation and fibrinolysis more rapidly than once-daily subcutaneous nadroparin in patients with proximal DVT (p < 0.05).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: